Back

CAS12e (CASX2) CLEAVAGE OF CCR5: IMPACT OF GUIDE RNA LENGTH AND PAM SEQUENCE ON CLEAVAGE ACTIVITY

Armstrong, D. A.; Hudson, T. R.; Hodge, C. A.; Hampton, T. H.; Howell, A. L.; Hayden, M. S.

2023-01-02 molecular biology
10.1101/2023.01.02.522476 bioRxiv
Show abstract

CRISPR/Cas is under development as a therapeutic tool for the cleavage, excision, and/or modification of genes in eukaryotic cells. While much effort has focused on CRISPR/Cas from Streptococcus pyogenes (SpCas9) and Staphylococcus aureus (SaCas9), alternative CRISPR systems have been identified using metagenomic datasets from non-pathogenic microbes, including previously unknown class 2 systems, adding to a diverse toolbox of gene editors. The Cas12e (CasX1, CasX2) endonucleases from non-pathogenic Deltaproteobacteria (DpeCas12e) and Planctomycetes (PlmCas12e) are more compact than SpCas9, have a more selective protospacer adjacent motif (PAM) requirement, and deliver a staggered cleavage cut with 5-7 base overhangs. We investigated varying guide RNA (spacer) lengths and alternative PAM sequences to determine optimal conditions for PlmCas12e cleavage of the cellular gene CCR5 (CC-Chemokine receptor-5). CCR5 encodes one of two chemokine coreceptors required by HIV-1 to infect target cells, and a mutation of CCR5 (delta-32) is responsible for HIV-1 resistance and reported cures following bone marrow transplantation. Consequently, CCR5 has been an important target for gene editing utilizing CRISPR, TALENs, and ZFNs. We determined that CCR5 cleavage activity varied with the target site, guide RNA length, and the terminal nucleotide in the PAM sequence. Our analyses demonstrated a PlmCas12e PAM preference for purines (A, G) over pyrimidines (T, C) in the fourth position of the CasX2 PAM (TTCN). These analyses have contributed to a better understanding of CasX2 cleavage requirements and will position us more favorably to develop a therapeutic that creates the delta-32 mutation in the CCR5 gene in hematopoietic stem cells.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
The CRISPR Journal
33 papers in training set
Top 0.1%
22.6%
2
Nucleic Acids Research
1128 papers in training set
Top 0.9%
14.4%
3
Cell Reports Methods
141 papers in training set
Top 0.4%
6.3%
4
PLOS Genetics
756 papers in training set
Top 4%
3.6%
5
PLOS ONE
4510 papers in training set
Top 42%
3.1%
6
eLife
5422 papers in training set
Top 29%
3.1%
50% of probability mass above
7
Scientific Reports
3102 papers in training set
Top 45%
2.6%
8
iScience
1063 papers in training set
Top 10%
2.1%
9
ACS Synthetic Biology
256 papers in training set
Top 1%
1.8%
10
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 1%
1.8%
11
BMC Genomics
328 papers in training set
Top 2%
1.7%
12
Frontiers in Genetics
197 papers in training set
Top 5%
1.7%
13
Journal of Biological Chemistry
641 papers in training set
Top 2%
1.7%
14
PLOS Biology
408 papers in training set
Top 10%
1.7%
15
Nature Communications
4913 papers in training set
Top 53%
1.5%
16
Cell Reports
1338 papers in training set
Top 27%
1.3%
17
Journal of Molecular Biology
217 papers in training set
Top 2%
1.2%
18
mBio
750 papers in training set
Top 9%
1.2%
19
Cell Chemical Biology
81 papers in training set
Top 3%
1.0%
20
ACS Chemical Biology
150 papers in training set
Top 2%
0.9%
21
RNA Biology
70 papers in training set
Top 0.4%
0.9%
22
BMC Biology
248 papers in training set
Top 3%
0.9%
23
Cell Genomics
162 papers in training set
Top 6%
0.8%
24
Communications Biology
886 papers in training set
Top 21%
0.8%
25
Mobile DNA
27 papers in training set
Top 0.2%
0.7%
26
Viruses
318 papers in training set
Top 6%
0.7%
27
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.6%
0.7%
28
Biomolecules
95 papers in training set
Top 3%
0.6%
29
PLOS Pathogens
721 papers in training set
Top 10%
0.6%
30
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.5%
0.6%